Peptisyntha


Managing Director:

Patrice Locht


Peptisyntha

310 rue de Ransbeek
1120 Brussels
Belgium
 
Human Resources Contact:
Phone:+32 2 263 1411

Get Driving Directions:

Get Directions

>>> News <<< Click here to read Peptisyntha's most recent successful FDA Inspection

Core Capabilities

  • Solid-phase peptide synthesis (SPPS)
  • Liquid-phase peptide synthesis (LPPS)
  • Hybrid strategies (SPPS-LPPS)
  • Complex peptides and peptidomimetics
  • Peptide-conjugations (PEGs, proteins, lipids, carbohydrates)
  • Cyclic peptides & peptides with multiple disulfide bridges
  • Short peptides (10-12 residues), often with no HPLC purification
  • Arginine-rich peptides


Peptisyntha Facility Capacities

Compliance Approvals

  • 6 FDA inspections: Most recently February 2015
  • 2011: Belgian Health Authorities on behalf of EMA
  • DMF filing experience: USA, Europe, Japan, Australia, Canada, New Zealand

Facility Legacy

Founded in 1987, Peptisyntha was a member of the Solvay group until being acquired by CordenPharma in October 2013. Peptisyntha has built 26 year track record of success in supplying pharmaceutical and biotech companies with small to commercial scale cGMP peptide API manufacturing using world-class cost-effective production processes. Through expertise and capabilities in all synthetic manufacturing technologies, Peptisyntha assesses and customized their manufacturing approach to achieve the most effective manufacturing process for their customers.

Peptisyntha has developed a portfolio of innovative proprietary technologies with the objective to shorten synthetic processes / reduce the number of steps, control quality, and simplify (or eliminate) HPLC purifications for short peptides. 

History

  • 1987: Peptisyntha founded on the Solvay Campus
  • 1996: First pre-approval FDA inspection for a major peptide made by Peptisyntha for the worldwide market
  • 2001: Completion of production plant extension
  • 2006-2008: Additional capabilities, further kilo-lab capacity, new QC/microbiology labs, new warehouse
  • 2011: Solid-phase peptide production units added
  • 2013: FDA inspection, no 483 form. Total of 5 successful FDA inspections
  • October 2013: Peptisyntha acquired by ICIG (International Chemical Investor Group) to join CordenPharma